Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population

摘要

To the Editor: Psoriasis is a chronic inflammatory proliferative disease mediated by T lymphocytes under a multi-gene genetic background.[1] Moreover, its pathogenesis is not fully understood. Recent research shows that T cell-mediated immune inflammation plays a key role in the pathophysiology of psoriasis, and its most common downstream mediator, interleukin (IL)-17, is the primary effector cytokine in this condition. Secukinumab is a high-affinitive, fully humanized, G1κ monoclonal antibody that can simultaneously block IL-17A from multiple sources.[2] In a global, core, phase III trial, secukinumab was confirmed to rapidly improve psoriasis symptoms; however, the efficacy of its use in Chinese population remains unknown. This study was performed in a Chinese population for a period of 16 weeks to explore the efficacy and safety of secukinumab after its introduction in clinical settings in May 2019.